BTT-266

• Description:

  BTT-266 is an antagonist forcalcium channel, through suppression of the CaVα1-AID-CaVβ3 interaction, with a Ki of 1.4 μM. BTT-266 modulates the activation of voltage-dependent CaV2.2. BTT-266 exhibits analgesic efficacy against neuropathic pain in rats model[1].

• UNSPSC:

  12352005

• Target:

  Calcium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/btt-266.html

• Purity:

  98.90

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=CC(C(N2N=C(CC2C3=CN(C4=CC=CC=C4)N=C3C5=CC=C(C)C=C5)C6=CC=C(OC)C=C6)=O)=C1)O

• Molecular Formula:

  C34H28N4O4

• Molecular Weight:

  556.61

• References & Citations:

  [1]Chen X, et al., Small-molecule CaVα1⋅CaVβ antagonist suppresses neuronal voltage-gated calcium-channel trafficking. Proc Natl Acad Sci U S A. 2018 Nov 6;115 (45) :E10566-E10575.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2413939-89-4]